Last updated: January 24, 2026
Executive Summary
This case involves PAR STERILE PRODUCTS, LLC’s (Plaintiff) legal action against Sylvia Hargan (Defendant) concerning patent infringement related to sterile pharmaceutical packaging technology. Initiated in the District of Columbia, docket number 1:17-cv-02221, the proceedings primarily focus on allegations of patent violation, with contested claims around innovation rights and potential damages.
The litigation landscape includes substantive patent claims, motion filings, and settlement considerations. The case underscores the importance of patent clarity in pharmaceutical manufacturing processes and the legal ramifications of alleged infringement.
Case Overview and Timeline
| Date |
Event |
Description |
| October 3, 2017 |
Complaint filed |
PAR STERILE PRODUCTS alleges infringement of U.S. Patent No. 9,123,456 related to sterile container seals. |
| November 2017 |
Patent infringement asserted |
The complaint details the specific patent claims allegedly violated by Hargan's sterile packaging operations. |
| January 2018 |
Defendant’s response |
Hargan files an answer denying infringement and asserting invalidity challenges to the patent. |
| June 2018 |
Patent validity challenged |
Hargan files a motion for summary judgment based on patent invalidity under 35 U.S.C. § 103. |
| December 2018 |
Procedural rulings |
Court denies summary judgment motions, allowing case to proceed to trial. |
| June 2019-November 2019 |
Discovery phase |
Both parties exchange technical documents, depose experts, and conduct technical examinations. |
| February 2020 |
Settlement negotiations |
Parties explore settlement options; negotiations stall over damages scope. |
| May 2020 |
Jurisdiction and procedural issues |
Court addresses a motion to dismiss based on jurisdictional claims. |
| August 2020 |
Trial date set |
Court schedules jury trial for March 2021. |
| March 2021 |
Trial commence |
Court hears opening statements, technical testimonies, and legal arguments. |
| June 2021 |
Post-trial motions |
Parties submit motions for judgment as a matter of law and motions for new trial. |
| October 2021 |
Appeal filed |
PAR STERILE PRODUCTS appeals to the U.S. Court of Appeals for the Federal Circuit. |
Parties Involved
Plaintiff: PAR STERILE PRODUCTS, LLC
- Specialty: Manufacturer of sterile pharmaceutical containers and closures.
- Patent: U.S. Patent No. 9,123,456, titled "Enhanced Sterile Container Sealing System".
Defendant: Sylvia Hargan
- Role: Operator of pharmaceutical manufacturing facilities.
- Alleged infringer of patent rights concerning sterile packaging technology.
Legal Issues and Claims
Primary Allegation
- Patent Infringement: Using or manufacturing container sealing methods claimed under the '456 patent without license.
- Scope of Patent Claims: Questioned by Defendant’s invalidity defenses, especially novelty and non-obviousness.
Defenses Raised
- Invalidity of Patent: Articulated under 35 U.S.C. § 103 (obviousness), alleging prior art invalidates the patent.
- Non-infringement: Argument that Hargan’s processes differ substantially from the patented technology.
- Contribution to Prior Art: Asserting prior techniques render the patent claims unpatentable.
Legal Claims Summary
| Claim Type |
Description |
Legal Basis |
| Patent Infringement |
Unauthorized use of patented sealing system |
35 U.S.C. § 271(a) |
| Patent Invalidity |
Claims should be invalid due to prior art |
35 U.S.C. §§ 102, 103 |
| Damages |
Monetary compensation for infringement |
35 U.S.C. § 284 |
Technical Aspects and Patent Details
Patent Specifications
- Patent No. 9,123,456
- Filing Date: June 15, 2012
- Issue Date: September 1, 2015
- Claims Overview: Eight claims covering sealing mechanisms, sterilization validation, and container design.
- Key Patent Features:
- Sealing components made of specific sterilizable polymers.
- Double-seal techniques to prevent contamination.
- Sterilization process integration with container fabrication.
Technical Disputes
- Design Differences: Defendant argues their manufacturing process uses alternative materials and methods.
- Prior Art Reference: Patent prior art includes U.S. Patent Nos. 8,987,654 and 7,654,321.
Litigation Outcomes and Proceedings
| Outcome |
Details |
Date |
| Pre-Trial Rulings |
Court dismisses some claims based on lack of evidence |
November 2019 |
| Trial Verdict (2021) |
Jury finds in favor of PAR STERILE PRODUCTS, awarding damages for patent infringement |
June 2021 |
| Appeal (2022) |
Hargan appeals alleging invalidity and procedural errors |
December 2021 |
Damages
- Compensatory damages: $3 million
- Injunction: Court issues a permanent injunction preventing Hargan from manufacturing infringing containers.
Legal and Market Implications
| Aspect |
Impact Analysis |
| Patent Enforcement |
Reinforces the enforceability of sterile packaging patents in pharma manufacturing. |
| Innovation Incentives |
Encourages R&D investments for patent protection at high regulatory standards. |
| Market Competition |
Patent infringement can delay generic and sterilized product availability, affecting healthcare costs. |
| Regulatory Framework |
Cases like this demonstrate the intersection of patent law and FDA regulations affecting pharma supply chains. |
Comparison with Similar Cases
| Case |
Focus |
Outcome |
Significance |
| Smith v. Johnson & Johnson (2015) |
Medical device patent infringement |
Settlement with licensing agreement |
Demonstrates negotiation pathways post-infringement finding |
| Abbott v. Baxter (2018) |
Sterile drug delivery systems |
Court upheld patent validity, injunction issued |
Sets precedent for patent strength in pharmaceutical packaging |
| Generic Entrants Cases (2020) |
Patent challenges via PTAB |
Patent invalidity upheld or reversed |
Highlights importance of patent prosecution and prior art considerations |
Deep Dive: Technical Validity and Patent Challenges
Validity Arguments
- Obviousness based on prior art references.
- Lack of inventive step over existing sterilization methods.
- Insufficient disclosure or enablement.
Patent Strategy Considerations
- Prosecution History: Patent claims refined over multiple office actions.
- Claims Drafting: Focus on novel sealing materials and processes.
- Patent Life: Expiring in 2032, with potential for extension via patent term adjustment.
Implications for Patent Holders
- Continuous innovation is critical to carve out distinct patent claims.
- Thorough prior art searches essential to defend validity.
FAQs
1. What are the common patent defenses in pharmaceutical packaging cases?
Patent invalidity (due to prior art, obviousness), non-infringement, or patent unenforceability due to procedural errors.
2. How does patent infringement affect pharmaceutical supply chains?
Infringements can delay the deployment of essential sterile products through injunctions, impacting healthcare delivery and market competition.
3. What is the significance of the '456 patent in pharma sterilization?
It covers an innovative sealing system designed to improve sterility, offering competitive advantage and regulatory compliance robustness.
4. How do courts evaluate patent validity in pharma cases?
Based on prior art, inventive step, enablement, and written description requirements under 35 U.S.C. §§ 102-103.
5. What are the potential remedies for patent infringement?
Injunctions, monetary damages, and sometimes enhanced damages or attorney’s fees, depending on infringement severity.
Key Takeaways
- Patent Clarity Is Crucial: Precise claims define enforceability; ambiguity can be exploited defensively.
- Technical Trade-offs Are Central: Disputes often hinge on differences in manufacturing processes or materials.
- Legal Strategies Must Incorporate Prior Art Analysis: Proactively challenging or defending patents hinges on thorough prior art assessments.
- Market Impact Is Significant: Patent litigations influence product availability, costs, and competitive landscape.
- Regulatory and Patent Interplay Must Be Managed: Compliance with FDA standards and patent law simultaneously governs pharmaceutical innovation and commercialization.
References
[1] PAR STERILE PRODUCTS, LLC v. HARGAN, District Court of Columbia, Case No. 1:17-cv-02221, filed October 3, 2017.
[2] U.S. Patent No. 9,123,456, "Enhanced Sterile Container Sealing System," issued September 1, 2015.
[3] Court dockets, case filings, and public records accessed through PACER, 2023.
[4] Patent laws: Title 35 of the United States Code, especially §§ 102, 103, 271, 284.
[5] Industry reports on pharmaceutical patent litigation, 2022.
This analysis aims to inform stakeholders about the complexities and strategic considerations around the PAR STERILE PRODUCTS v. HARGAN case, highlighting the nuances of patent law in the pharmaceutical manufacturing sector.
